Market Overview

Rodman & Renshaw Changes Rating on Rexahn Pharmaceuticals to Market Perform

Share:

Rodman & Renshaw has changed its rating on Rexahn Pharmaceuticals (NYSE: RNN) from Under Review to Market Perform after the company revealed a change in focus to its oncology portfolio.

Posted-In: Rodman & RenshawUpgrades Intraday Update Analyst Ratings

 

Related Articles (RNN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
PPLMacquarieUpgrades
ROICCapital One FinancialUpgrades
REZIOppenheimerDowngrades
SNAPJP MorganUpgrades
FBKRaymond JamesDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Wunderlich Raises PT on Bank of the Ozarks to $32

Semiconductor Space Goes Crazy on Wednesday